A BREAST cancer drug for women who have stopped responding to Herceptin has been launched in the UK.
Kadcyla - or T-DM1 - is given to patients who have failed on conventional treatment with Herceptin and chemotherapy.
It is only suitable for patients with the defective Her2 gene and trial results have shown it can extend life by six months compared with two other drugs, lapatinib (Tyverb) and capecitabine (a type of chemotherapy).
Kadcyla is designed to penetrate cancer cells and destroy them from within and, because its action is so precise, a normally toxic form of chemotherapy can be used. Clinical trial results have shown that women on Kadcyla survived 30.9 months compared with 25.1 months for patients treated with lapatinib and capecitabine.
They also suffered fewer side-effects such as diarrhoea and vomiting.
James Jopling, director for Scotland at Breakthrough Breast Cancer, said: "Kadcyla has more manageable side effects and gives a better quality of life than that provided by existing treatments, which could make a huge difference."
Kadcyla is an antibody-drug conjugate which means it uses a "stable linker" to join Herceptin and a powerful chemotherapy together.
This enables a two-stage attack on cancer cells. Kadcyla blocks the growth signals that enable cancer cells to survive before releasing chemotherapy directly into the cells. It is administered intravenously once every three weeks.
The drug has not been appraised for use on the NHS by the Scottish Medicines Consortium.
Mr Jopling said: "Women with secondary breast cancer deserve the extra months that medicines such as Kadcyla offer."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article